Redeye initiates coverage of Cereno Scientific, a biotech company developing drugs to treat both rare and common cardiovascular diseases. Cereno is about to initiate a phase II clinical trial with lead candidate CS1 in pulmonary arterial hypertension, a commercially attractive orphan disease.